Supplemental material for JAAD publication titled: "A phase III open-label, randomized multicenter study to evaluate efficacy and safety of secukinumab in pediatric patients with moderate to severe plaque psoriasis: 24-week results" to be published in Journal of the American Academy of Dermatolog
Psoriatic disease is a multifaceted disorder, which develops in the skin, its appendages and joints....
OBJECTIVE: To report the 5-year efficacy and safety of secukinumab in the treatment of patients with...
Supplementary Appendices (i-iii) to the research letter Risk of respiratory infection in patients wi...
Supplemental material for JAAD publication titled: "Secukinumab treatment demonstrated high efficac...
<p><b>Article full text</b></p> <p><br></p> <p>The full text of this article can be found here<b>....
<p><b>Article full text</b></p> <p><br></p> <p>The full text of this article can be found here<b>....
Supplemental Material, Supplementary_Material_revised_Oct.10 for Guselkumab for the Treatment of Mod...
Title: Secukinumab efficacy and safety in Indian patients with moderate-to-severe plaque psoriasis: ...
Supplemental material, Supplemental__Figure_1 for Effectiveness and safety of secukinumab for psoria...
OBJECTIVE: To report the 5-year efficacy and safety of secukinumab in the treatment of patients with...
Item does not contain fulltextBACKGROUND: Secukinumab, a fully human anti-interleukin-17A monoclonal...
<p><b>Article full text</b></p> <p><br></p> <p>The full text of this article can be found here<b>....
Supplemental material, Supplement_Table_S3 for Effectiveness and safety of secukinumab for psoriasis...
This is additional supporting information for an article entitled "Modifiable Lifestyle and Environm...
OBJECTIVE: To report the 5-year efficacy and safety of secukinumab in the treatment of patients with...
Psoriatic disease is a multifaceted disorder, which develops in the skin, its appendages and joints....
OBJECTIVE: To report the 5-year efficacy and safety of secukinumab in the treatment of patients with...
Supplementary Appendices (i-iii) to the research letter Risk of respiratory infection in patients wi...
Supplemental material for JAAD publication titled: "Secukinumab treatment demonstrated high efficac...
<p><b>Article full text</b></p> <p><br></p> <p>The full text of this article can be found here<b>....
<p><b>Article full text</b></p> <p><br></p> <p>The full text of this article can be found here<b>....
Supplemental Material, Supplementary_Material_revised_Oct.10 for Guselkumab for the Treatment of Mod...
Title: Secukinumab efficacy and safety in Indian patients with moderate-to-severe plaque psoriasis: ...
Supplemental material, Supplemental__Figure_1 for Effectiveness and safety of secukinumab for psoria...
OBJECTIVE: To report the 5-year efficacy and safety of secukinumab in the treatment of patients with...
Item does not contain fulltextBACKGROUND: Secukinumab, a fully human anti-interleukin-17A monoclonal...
<p><b>Article full text</b></p> <p><br></p> <p>The full text of this article can be found here<b>....
Supplemental material, Supplement_Table_S3 for Effectiveness and safety of secukinumab for psoriasis...
This is additional supporting information for an article entitled "Modifiable Lifestyle and Environm...
OBJECTIVE: To report the 5-year efficacy and safety of secukinumab in the treatment of patients with...
Psoriatic disease is a multifaceted disorder, which develops in the skin, its appendages and joints....
OBJECTIVE: To report the 5-year efficacy and safety of secukinumab in the treatment of patients with...
Supplementary Appendices (i-iii) to the research letter Risk of respiratory infection in patients wi...